Responses
Immunotherapy biomarkers
Original research
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
